Categories AlphaGraphs, Earnings, Health Care
Earnings: Regeneron Pharmaceuticals (REGN) Q1 profit falls; revenue up 7%
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Thursday reported a decline in adjusted earnings for the first quarter of 2023, despite an increase in revenues.
Total revenues moved up 7% year-over-year to $3.16 billion in the three months ended March 2023. Excluding Ronapreve, revenues came in at $2.94 billion.
Meanwhile, the biotechnology firm’s first-quarter adjusted earnings dropped to $10.09 per share from $11.49 per share in the same period of 2022. Unadjusted profit was $818 million or $7.17 per share, compared to $974 million or $8.61 per share last year.
“We remain focused on advancing our robust pipeline at all stages, and we were pleased to announce positive data from a late-stage study of Dupixent in COPD and make continued progress with our costimulatory and bispecific antibody candidates in oncology,” said the company’s CEO Leonard Schleifer.
Prior Performance
Most Popular
CCL Earnings: Highlights of Carnival Corporation’s Q4 2025 results
Cruise operator Carnival Corporation & plc (NYSE: CCL) on Friday reported an increase in revenue and adjusted earnings for the fourth quarter of fiscal 2025. Earnings topped analysts' expectations. Revenues
Lamb Weston (LW) Q2 2026 Earnings: Key financials and quarterly highlights
Lamb Weston Holdings, Inc. (NYSE: LW) reported its second quarter 2026 earnings results today. Net sales inched up 1% year-over-year to $1.62 billion. Net sales at constant currency remained flat.
Paychex reports higher Q2 FY26 revenue and earnings; EPS beats estimates
Paychex Inc. (NASDAQ: PAYX) on Friday reported stronger-than-expected adjusted earnings for the second quarter of fiscal 2026. Revenues grew 18% year-over-year. The Rochester-based human capital management solutions provider reported revenues
